Results 31 to 40 of about 13,753,339 (302)

Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors

Viruses, 2021
Identification of Na+/taurocholate co-transporting polypeptide (NTCP) as high-affinity hepatic entry receptor for the Hepatitis B and D viruses (HBV/HDV) opened the field for target-based development of cell-entry inhibitors. However, most of the HBV/HDV
Michael Kirstgen, Kira Alessandra Alicia Theresa Lowjaga, Simon Franz Müller, Nora Goldmann, Felix Lehmann, Dieter Glebe, Karl-Heinz Baringhaus, Joachim Geyer   +7 more
doaj   +1 more source

Epidemiology of hepatitis B [PDF]

The Pediatric Infectious Disease Journal, 1993
An estimated 200,000 to 300,000 hepatitis B virus infections occur annually in the United States. With acute infection, symptoms develop in fewer than 5% of infants, 5 to 15% of children between the ages of 1 and 5 years and 33 to 50% of older children and adults. However, the risk of chronic infection after acute infection is inversely proportional to
openaire   +3 more sources

Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada

BMJ Open
Objectives To collect and document the numerous barriers that people living with hepatitis B (PLHB) encounter when trying to access their hepatitis B virus (HBV) medications.Design Researchers collected qualitative data through 24 online interviews.
Sophie Jacob, Michaela Jackson, Yasmin Ibrahim, Catherine Freeland, Beatrice Zovich, Chari Cohen   +5 more
doaj   +1 more source

Best practices for engaging with affected communities: chronic hepatitis B as a case study

Infectious Diseases of Poverty
Hepatitis B is the single most common cause of liver cancer, affecting > 250 million people worldwide (mostly in resource limited communities) and killing > 1 million people annually. The condition is marked by poor rates of diagnosis (14%) and treatment
Thomas Tu, Nafisa Yussf, Lien Tran, Kim Ngo, Su Wang, Adi Mondel, Isabelle Purcell, Jacki Chen, Wendy Lo, Bright Ansah, Kenneth Kabagambe, Soumen Basu, Dee Lee, Supa Chantschool, Chris Munoz, Ivana Dragojevic, Marko Korenjak, Fiona Borondy-Jenkins, Yasmin Ibrahim, Beatrice Zovich, Chari Cohen   +20 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Identifying barriers to hepatitis B and delta screening, prevention, and linkage to care among people who use drugs in Philadelphia, Pennsylvania, USA

Harm Reduction Journal
Background People who use drugs (PWUD) are at increased risk for blood-borne viruses, including hepatitis B (HBV) and delta (HDV). Despite the public health threats both viruses present, awareness remains low among at-risk communities and providers who ...
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Amy Jessop, Rachel Holbert, Fiona Borondy-Jenkins, Quinn Plunkett, Chari Cohen   +9 more
doaj   +1 more source

Socioecological barriers interrupting hepatitis B and liver cancer care engagement among USA immigrant groups

Academia Oncology
Introduction: In the United States, immigrant communities of Asian and Pacific Islander (API), African and Caribbean origin are disproportionately burdened by hepatitis B and primary liver cancer (hepatocellular carcinoma).
Beatrice Zovich, Fiona Borondy-Jenkins, Suzanne J. Block, Shreya Koirala, Thomas Chen, Kate Moraras, Chari Cohen   +6 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Dismantling Barriers to Hepatitis B and Delta Screening, Prevention, and Linkage to Care among the PWUD Community in Philadelphia

Viruses
The prevalence of hepatitis B and delta viruses (HBV/HDV) among people who use drugs (PWUD) remains largely unknown. In the context of one Philadelphia-based harm reduction organization (HRO), this study aimed to assess HBV/HDV prevalence and facilitate ...
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Rachel Holbert, Jason Zambrano, Daljinder Bhangoo, Chari Cohen, Richard W. Hass, Amy Jessop   +10 more
doaj   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source